After multidisciplinary discussion, it was determined that the risks outweighed the potential benefits, even in cases of human epidermal growth factor receptor 2-positive tumors, where trastuzumab would have posed a risk of severe cardiotoxicity, especially in patients already suffering from heart disease. This evidence concerns the gene ERBB2 and heart disorder.